Comparing the current results to its competitors, Shattuck Labs Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.73 %, recorded in the same quarter.
Shattuck Labs Inc , slower than the average decrease reported by the company's competitors of -82.56 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -82.56 %
Shattuck Labs Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes large pharmaceutical and biotechnology firms, academic institutions, government agencies, and other research organizations focused on developing therapies for immune-mediated diseases such as inflammatory bowel disease (IBD). Key competitors with commercialized or developing therapies in this area include Abbvie, Absci Corporation, Johnson & Johnson, Merck, Novartis, Pfizer, Roche/Genentech, Sanofi, Takeda, and Teva. For its lead product candidate, SL-325, the company is aware of other clinical-stage therapeutics targeting the TL1A/DR3 axis, including TL1A-targeting antibodies like duvakitug developed by Absci Corporation. Many competitors possess greater financial resources and expertise in drug development and commercialization. Industry consolidation through mergers and acquisitions may further concentrate resources among fewer competitors, while smaller or early-stage companies may also present competition through collaborations with larger firms.
April 9, 2024
In an unprecedented oral presentation at the highly esteemed American Association for Cancer Research (AACR) Annual Meeting 2024, Shattuck Labs, a biomedical research powerhouse, has unveiled groundbreaking preclinical data that significantly propels the field of immune checkpoint blockade (ICB) acquired resistance, which has been notoriously difficult to treat.In their presentation, Shattuck Labs has identified the aberrant expression of the Tripartite Motif Containing 7 (TRIM7), as a pivotal driver responsible for the emerging of this acquired resistance. This trailblazing identification proves to be a stepping stone towards understanding the detailed mechanisms that underlie the complex resistance develop...
Shattuck Labs, Inc. has recently transfixed the medical community after revealing striking initial topline indications from its ongoing Phase 1 A/B Dose Expansion Clinical Trial. The trial, centered on its product SL-172154 combined with Azacitidine, targeted patients suffering from high-risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML). The investigational study revealed a striking 79% Objective Response Rate (ORR) in frontline HR-MDS patients. This largely consists of subjects with TP53 mutations. An encouragingly high initial complete response (CR)/marrow complete response (mCR) rate of 64% accompanied this. These figures are a testament to the potentia...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Shattuck Labs Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Shattuck Labs Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
